Multiple injections of bevacizumab improve best-corrected visual acuity (BCVA) and central macular thickness in patients with persistant clinically significant macular oedema (CSME), according to a paper in the Archives of Ophthalmology.
Dr Ranjan Rajendram et al., Moorfields Eye Hospital, London, UK, completed a two year single-centre randomized controlled trial on 80 CSME patients who were randomized to receive either bevacizumab or macular laser therapy (MLT). The primary outcome measure was difference in ETDRS BCVA between arms and the secondary outcome measures were mean change in BCVA, proportion gaining at least 15 and at least 10 ETDRS letters, losing fewer than 15 and at least 30 letters, change in central macular thickness, ETDRS retinopathy severity and safety outcomes.
In the bevacizumab group mean ETDRS BCVA was 64.4 and in the MLT group it was 54.8. A median of nine ETDRS letters and 2.5 letters were gained for the bevacizumab and MLT groups, respectively. Mean reduction in central macular thickness was 146 µm in the bevacizumab group, compared to 118 µm in the MLT group. The mean number of treatments administered over the two year period was 13 and 4 for bevacizumab and MLT, respectively.